Protagenic Therapeutics, Inc. (NASDAQ:PTIX) Short Interest Up 59.0% in March

Protagenic Therapeutics, Inc. (NASDAQ:PTIX) was the recipient of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 185,700 shares, an increase of 59.0% from the February 28th total of 116,800 shares. Based on an average trading volume of 2,030,000 shares, the short-interest ratio is presently 0.1 days. Approximately 3.0% of the shares of the stock are short sold.

Protagenic Therapeutics Stock Performance

Shares of PTIX traded down $0.03 during midday trading on Monday, hitting $0.20. 56,913 shares of the company traded hands, compared to its average volume of 2,103,711. The stock has a market cap of $1.45 million, a price-to-earnings ratio of -0.16 and a beta of 0.43. Protagenic Therapeutics has a 52 week low of $0.21 and a 52 week high of $1.87. The firm has a 50 day moving average of $0.31 and a 200-day moving average of $0.49.

About Protagenic Therapeutics

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.